

## R&D Pipeline

antibody  
 protein  
 small molecule  
 © New Molecular Entity  
 Updated since Dec. 31, 2022  
 Updated since Sep. 30, 2023

### Nephrology


Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approve d	
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	KR						[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia
			CN TW						
KHK7791 Tenapanor Hydrochloride Oral	NHE3 Inhibitor	Hyperphosphatemia in Patients on Dialysis	JP						[Ardelyx] product name in Japan: Phozevel
KRN1493 Cinacalcet Hydrochloride Oral	Calcimimetic	Primary Hyperparathyroidism	HK						[NPS Pharmaceuticals] product name in Japan: Regpara

Since the development of KW-3357 for preeclampsia was discontinued in Japan, the relevant information was deleted from this table.

### Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks	
				Ph I	Ph II	Ph III	Filed	Approve d		
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	KW IL						[In-House] POTELLIGENT product name in Japan, US and Europe: Poteligeo	
			ME							
			RS							
			TW SG							
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation	JP						[Amgen K-A] product name in Japan: G-Lasta	
KK2260 Injection	EGFR-TfR1 Bispecific Antibody	Solid Tumor	JP NA							[In-House] Bispecific antibody utilized REGULGENT Fully human antibody production technology

## R&D Pipeline



antibody



protein



small molecule

© New Molecular Entity



Updated since Dec. 31, 2022



Updated since Sep. 30, 2023

### Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Ankylosing Spondylitis	TH	→					[Amgen K-A] product name in Japan and Asia: Lumicef
		Non-radiographic Axial Spondyloarthritis	TH	→					
		Palmoplantar Pustulosis	JP	→					
		Systemic Sclerosis	JP	→					
@KHK4083/AMG 451 Rocatinimab Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP NA Europe Middle East CN Asia Oceania others	→					[In-House] POTELLIGENT Fully human antibody production technology Collaboration agreement with Amgen for the development of KHK4083/AMG 451 in all the countries except for Japan.
@KK4277 Injection	Anti-PTPRS Humanized Antibody	Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus	JP Asia	→					[SBI Biotech] POTELLIGENT

### Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	Tumor Induced Osteomalacia (TIO)	OM QA UAE	→					[In-House] Fully human antibody production technology Jointly Developed with Ultragenyx in US and Europe product name in Japan, US and Europe: Crysvita
			KW BH	→					
			RS	→					
			ME MK	→					
		BA	→						
		X-linked Hypophosphatemia (XLH)	MO	→					
			RS	→					
			MK ME	→					
BA	→								
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Previously Untreated with Immunosuppressive Therapy	JP	→					[Amgen K-A] product name in Japan: Romiplate
		Treatment of Aplastic Anemia (AA) Which Is Refractory to Immunosuppressive Therapy or Immunosuppressive Therapy Being Not Suitable	Asia	→					
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Europe	→					[In-House] product name in Japan: Acoalan
			KHK4951 Tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Neovascular (wet) Age-Related Macular Degeneration	JP	→		